Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc., an emerging growth company, on September 18, 2017. The filing primarily serves to disclose a corporate investor presentation and provide an update on an ongoing equity offering program.
Key Financial Metrics and Capital Activity
The filing does not provide a full set of financial statements, revenue, profit, or cash flow metrics for a specific reporting period. However, it discloses the following capital activity under an "at-the-market" offering program:
- Program Capacity: Up to $75.0 million aggregate offering price.
- Shares Sold (Since June 30, 2017): 2,562,449 shares of common stock.
- Proceeds Received: Approximately $12.8 million (net of commissions).
Material Changes and Events
The primary material event reported is the execution of share sales under the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., which was originally entered into on March 30, 2017, and amended on August 28, 2017. Additionally, the company released an updated investor presentation containing clinical, development, collaboration, and financial updates.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the attached investor presentation (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. The company undertakes no obligation to update, supplement, or amend the materials in the presentation. No specific forward-looking guidance or risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation) for detailed clinical and financial updates, noting the disclaimer that this content is not formally "filed."
- Verify the remaining capacity of the $75.0 million at-the-market offering program.
- Confirm the current share count and dilution impact from the 2,562,449 shares sold since June 30, 2017.
- Check subsequent filings for any updates to the clinical development milestones mentioned in the presentation.